Intravenous isosorbide dinitrate will be presented next week as an investigational new drug candidate to treat COVID-19 at the Virginia Drug Discovery Consortium’s annual meeting VaDDRx 2022 in Richmond, Virginia.

Prior CERVOE.org posts have detailed how isosorbide dinitrate (ISDN) may have anti-SARS-Cov-2 activity.  These ideas are being presented at a meeting expressly dedicated to drug discovery for cardiopulmonary diseases including COVID.  The poster presented at the American Heart Association last November will be presented again on Tuesday, May 24 with updated information.  Although oral ISDN is available in the U.S. for cardiac angina, an intravenous (IV) formulation has not been FDA approved. In contrast, most countries in the world have IV ISDN listed in their national formulary. CERVOE.org is seeking partners to launch a pilot study through a clinical trial platform to investigate IV ISDN as a COVID drug, after an investigational new drug (IND) application with the FDA has been approved. Another drug option to treat hypoxia and complications of moderate to severe COVID offers the opportunity to save a life, whether that of civilian or a service member infected with SARS-CoV-2.